October 17, 2016 / 10:11 AM / 10 months ago

BRIEF-Contravir Pharmaceuticals CMX157 advances head-to-head Phase 2a clinical study

Oct 17 (Reuters) - Contravir Pharmaceuticals Inc

* CMX157 advances head-to-head phase 2A clinical study in Hepatitis B patients with favorable recommendation from DSMB

* Contravir expects to complete remaining two escalation cohorts and report top-line results by year-end 2016.

* Contravir Pharmaceuticals - begun enrolling next dosing group in hephase 2A dose-escalation study comparing safety and efficacy of contravir's CMX157 to tenofovir disoproxil fumarate Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below